Animal Models in Epileptic Spasms and the Development of Novel Treatment Options

J Clin Neurophysiol. 2022 Nov 1;39(7):529-537. doi: 10.1097/WNP.0000000000000496. Epub 2022 Mar 24.

Abstract

The infantile spasms (IS) syndrome is a catastrophic developmental epileptic encephalopathy syndrome characterized by an age-specific expression of epileptic spasms that are associated with extremely abnormal, oftentimes described as chaotic, interictal EEG pattern known as hypsarrhythmia. Patients with IS generally have poor neurodevelopmental outcomes, in large part because of the frequent epileptic spasms and interictal EEG abnormalities. Current first-line treatments such as adrenocorticotropic hormone or vigabatrin are often ineffective and are associated with major toxic side effects. There is therefore a need for better and safer treatments for patients with IS, especially for the intractable population. Hope is on the horizon as, over the past 10 years, there has been robust progress in the development of etiology-specific animal models of IS. These models have been used to identify potential new treatments for IS and are beginning to provide some important insights into the pathophysiological substrates for this disease. In this review, we will highlight strengths and weaknesses of the currently available animal models of IS in addition to new insights into the pathophysiology and treatment options derived from these models.

Publication types

  • Review

MeSH terms

  • Adrenocorticotropic Hormone / therapeutic use
  • Animals
  • Anticonvulsants / therapeutic use
  • Electroencephalography
  • Humans
  • Models, Animal
  • Spasm / chemically induced
  • Spasm / complications
  • Spasm / drug therapy
  • Spasms, Infantile* / drug therapy
  • Vigabatrin / therapeutic use

Substances

  • Vigabatrin
  • Adrenocorticotropic Hormone
  • Anticonvulsants